Literature DB >> 7074497

Probucol and familial hypercholesterolemia.

J Dauignon, D Bouthillier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7074497      PMCID： PMC1863297     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia.

Authors:  M J Mellies; P S Gartside; L Glatfelter; P Vink; G Guy; G Schonfeld; C J Glueck
Journal:  Metabolism       Date:  1980-10       Impact factor: 8.694

2.  Usefulness of probucol in treating primary hypercholesterolemia.

Authors:  M Enjalbert; S Lussier-Cacan; S DuBreuil-Quidoz; J LeLorier; J Davignon
Journal:  Can Med Assoc J       Date:  1980-10-18       Impact factor: 8.262

3.  Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.

Authors:  J LeLorier; S DuBreuil-Quidoz; S Lussier-Cacan; Y S Huang; J Davignon
Journal:  Arch Intern Med       Date:  1977-10

4.  [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].

Authors:  R E Tedeschi; B L Martz; H A Taylor; B J Cerimelle
Journal:  Nouv Presse Med       Date:  1980-10-30

5.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.